# Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

> **NCT00103571** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 600 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00103571
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 600 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103571, "Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00103571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*